Daniel C. McFarland, DO, and Yesne Alici, MD, discussed medical aid in dying in cancer care, New York’s safeguards, and the role of psycho-oncology.
|Poll|May 1, 2018
A 32-Year-Old Man With Lower Back Pain
Author(s)Cesar A. Moran, MD
A 32-year-old man presents with pain in the lower back of several weeks’ duration. What is your diagnosis?
Advertisement
A 32-year-old man presents with pain in the lower back of several weeks duration. During physical examination, a soft tissue mass is detected in the soft tissue of the lower back. Diagnostic imaging reveals a mass without mineralization. A surgical biopsy is obtained.
Based on the image shown, what is your diagnosis?
Advertisement
Related to this article
Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.
An analysis of the BENEFIT trial supports isatuximab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care in transplant-ineligible NDMM.
C. Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible framework in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
A patient-reported outcomes analysis from the phase 3 IRAKLIA trial showed higher satisfaction with subcutaneous isatuximab via on-body injector.
The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acting on a HER2 Result and Navigating Access to Therapy
2
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
3
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
4
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
5